Entasis Therapeutics Holdings Inc (ETTX)

Company Profile

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2018-09-26. The firm is focused on the discovery, development, and commercialization of targeted antibacterial products that address unmet medical needs to treat infections caused by multidrug-resistant pathogens. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), which is an intravenous, combination of sulbactam, an IV b-lactam antibiotic, and durlobactam, a novel broad-spectrum IV b -lactamase inhibitor (BLI) for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. Its second late-stage product candidate is zoliflodacin, which is an orally administered molecule being developed for the treatment of uncomplicated gonorrhea. Its third product candidate is ETX0282CPDP for the oral treatment of urinary tract infections. ETX0282CPDP is a combination of ETX0282, a novel oral BLI, with cefpodoxime proxetil (cefpodoxime), an oral b-lactam antibiotic.

Company Info

Entasis Therapeutics Holdings Inc

35 Gatehouse Drive

Waltham MASSACHUSETTS 02451

P: 17818100120.0

CEO: Manoussos Perros

Employees: 51

Website: https://www.entasistx.com/